Kiniksa (NASDAQ: KNSA) reports $677.5M ARCALYST revenue, strong cash

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc furnished an update on its 2025 financial performance. The company reported unaudited full-year 2025 ARCALYST net product revenue of $677.5 million. It also disclosed an unaudited gross-to-net figure of 8.4% for the year, indicating the difference between list prices and realized revenue after discounts and allowances. As of December 31, 2025, Kiniksa reported unaudited $414.1 million in cash, cash equivalents and short-term investments and stated that it had no debt. These figures were shared in a press release that is included as an exhibit.

0001730430false00017304302026-01-122026-01-12

​

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): January 12, 2026

​

Kiniksa Pharmaceuticals International, plc

(Exact name of Registrant as Specified in Its Charter)

​

​	​	​	​	​
England and Wales	​ ​ ​	001-730430	​ ​ ​	98-1795578
(State or other jurisdiction of incorporation or organization)	​	(Commission File Number)	​	(I.R.S. Employer Identification No.)

​

105 Piccadilly, Second Floor

London, W1J 7NJ

England, United Kingdom
(781) 431-9100

(Address, zip code and telephone number, including area code of principal executive offices)

​

Kiniksa Pharmaceuticals Corp.

100 Hayden Avenue

Lexington, MA, 02421

(781) 431-9100

(Address, zip code and telephone number, including area code of agent for service)

​

23 Old Bond Street, Floor 3

London, W1S 4PZ

England, United Kingdom

(Former Name or Former Address, if Changed Since Last Report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

	​		​
Title of each class	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of each exchange on which registered
Class A Ordinary Shares $0.000273235 nominal value	​	KNSA	​	The Nasdaq Stock Market LLC
​	​	​	​	(Nasdaq Global Select Market)

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

​

Item 2.02. Results of Operations and Financial Condition 

On January 12, 2026, Kiniksa Pharmaceuticals International, plc (the “Company”) issued a press release announcing, among other things, that (i) ARCALYST net product revenue was $677.5 million for the full year 2025 (unaudited), (ii) gross-to-net was 8.4% for the full year 2025 (unaudited) and (iii) as of December 31, 2025 it had $414.1 million of cash, cash equivalents and short-term investments and no debt (unaudited). A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

​

Item 9.01. Financial Statements and Exhibits.

​

(d) Exhibits

​

	​
Exhibit No.	​ ​ ​	Description
​	​	​
99.1	​	Press Release issued by Kiniksa Pharmaceuticals International, plc, dated January 12, 2026
​	​	​
104	​	Cover Page Interactive Data File (embedded within the inline XBRL document)

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
​	​
Date: January 12, 2026	By:	/s/ Douglas Barry
​	​	Douglas Barry
​	​	Senior Vice President, Chief Legal Officer

​

​

​

​

FAQ

What financial update did Kiniksa (KNSA) provide for 2025?

Kiniksa reported unaudited full-year 2025 ARCALYST net product revenue of $677.5 million, along with key cash and gross-to-net metrics.

How much ARCALYST revenue did Kiniksa (KNSA) generate in 2025?

The company disclosed unaudited full-year 2025 ARCALYST net product revenue of $677.5 million.

What was Kiniksa’s 2025 gross-to-net for ARCALYST?

Kiniksa reported an unaudited full-year 2025 gross-to-net of 8.4%, reflecting the impact of discounts and allowances on ARCALYST sales.

What is Kiniksa’s cash position and debt level as of December 31, 2025?

As of December 31, 2025, Kiniksa reported unaudited $414.1 million in cash, cash equivalents and short-term investments and stated it had no debt.

What document contains the detailed financial information Kiniksa referenced?

The detailed unaudited financial information is included in a press release furnished as Exhibit 99.1 to this Form 8-K.

Is the 2025 financial information from Kiniksa audited?

No. The company specified that the 2025 ARCALYST revenue, gross-to-net, and cash figures are unaudited.